M&T Bank Corp bought a new position in shares of Covetrus, Inc. (NASDAQ:CVET – Get Rating) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 11,950 shares of the company’s stock, valued at approximately $39,000.
Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Covetrus by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 11,549,462 shares of the company’s stock worth $193,916,000 after acquiring an additional 322,572 shares in the last quarter. Wellington Management Group LLP lifted its stake in Covetrus by 6.2% in the 1st quarter. Wellington Management Group LLP now owns 8,357,496 shares of the company’s stock valued at $140,323,000 after buying an additional 485,051 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Covetrus by 3.2% in the 1st quarter. JPMorgan Chase & Co. now owns 4,945,606 shares of the company’s stock valued at $83,037,000 after buying an additional 151,302 shares in the last quarter. State Street Corp lifted its stake in Covetrus by 1.3% in the 1st quarter. State Street Corp now owns 3,843,625 shares of the company’s stock valued at $64,534,000 after buying an additional 49,718 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Covetrus by 36.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,501,140 shares of the company’s stock valued at $41,997,000 after buying an additional 661,866 shares in the last quarter. 92.20% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Separately, TheStreet raised shares of Covetrus from a “d+” rating to a “c-” rating in a research note on Wednesday, September 28th. One analyst has rated the stock with a sell rating and five have given a hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $20.00.
Covetrus Price Performance
Covetrus, Inc, together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers.
- Get a free copy of the StockNews.com research report on Covetrus (CVET)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.